The tobacco industry was surprised by the July 28 announcement from the U.S. regulator that the Food and Drug Administration (FDA) was looking to reduce the nicotine in traditional combustible cigarettes to non-addictive levels, and questioning the role of menthol. Our view is that any action is likely to be many years away, and is arguably balanced by the opportunity in Next Generation products for those who are well positioned. Our portfolio is concentrated on tobacco names with access to the Next Generation products, and in particular heat-not-burn, and thus should be well-placed.

Tobacco has long been a steady compounder. The industry has grown its earnings at 7% per year in U.S. dollars over the last decade, while paying a healthy yield of around 4%. By contrast, the MSCI World Index has grown its earnings at just 0.5% with a lower yield. The sector’s price-to-earnings multiple can be volatile, as shown at the end of July, but over the long term the relentless compounding has driven strong share price outperformance. The key to this compounding has been pricing power. Combining a concentrated industry with limits on advertising in most markets to constrain new entrants, along with a taxation regime that gives cover to price rises, makes for a perfect environment to raise prices steadily – price/mix is of the order of 5% annually. It is important to note that the industry’s compounding has happened in the face of regulatory pressure...

1 Source: FactSet, July 31, 2017.
compounding has happened in the face of regulatory pressure that has steadily reduced the volumes of cigarettes sold in Developed Markets, though some of the regulatory changes, such as the rising weight of taxation and advertising bans, have actually helped boost pricing power. While the July 28 announcement by the U.S. regulator is significant, we do not see it as a break with the model of the last 40 years of regulation.

Looking forward, we believe that some tobacco companies can continue to compound successfully, but it is becoming more important to be selective, just as in the case of other Consumer Staples, as described in last month’s update. With other Staples, one of the key issues is technological change, and the threat of a certain e-commerce giant. For tobacco, it is the ‘Next Generation’, or ‘Reduced Harm’ products that provide the threat – and the opportunity.

Our belief is that companies strongly positioned in these areas, in heat-not-burn or e-cigarettes, are likely to gain share at the expense of other players, and thus continue to compound. At the margin, the U.S. regulator’s move is likely to help this process.

It is understandable that the U.S. regulatory framework announced on July 28 spooked the markets. The new head of the FDA is aspiring to reduce the nicotine in combustible (i.e., traditional) cigarettes to non-addictive levels, while also expressing concern about the role that flavorings (notably menthol) play in attracting young people to smoking. However, it is important to note that the announcement was a press release rather than actual regulation, and that the process is likely to take multiple years, and may well result in a significant watering down of the proposals. Under the Tobacco Control Act, the FDA’s decisions must be based on scientific evidence, much of which may not yet be in place, meaning extensive research may be required. The tobacco industry will be ready to offer strong legal challenges which could delay or block any reforms, while elements of the Republican Congress and Trump’s base may not welcome government constraints on nicotine.

On the positive side, there was an explicit recognition in the FDA release that there are other less harmful means of delivering nicotine, a major endorsement of lower-risk Next Generation products, which are unlikely to have their nicotine content lowered. ‘Big Tobacco’ dominates the e-cigarette market, while the heat-not-burn category is led by Philip Morris International’s IQOS, which has already taken 12% of the Japanese market (and will be licensed to Altria in the U.S.), followed by BAT’s glo. The regulator’s attitude should help the approval of heat-not-burn in the U.S. and may even strengthen the case for favorable tax treatment compared to combustible cigarettes, as has been the case in other markets. This should ensure that the products have economics as good, or even better, than traditional cigarettes, once scale is reached.

Our view is that the world is a profoundly unpredictable place at present, and that this unpredictability is not reflected in a market where MSCI World Index is trading at close to 17 times the next 12 months’ earnings, which themselves include an assumption of double-digit earnings growth. As a result, we favor quality compounders, which can grow earnings steadily at high returns on operating capital. We put tobacco companies in that category, despite the regulatory noise, provided they are well placed in Next Generation products.

On the positive side, there was an explicit recognition in the FDA release that there are other less harmful means of delivering nicotine, a major endorsement of lower-risk Next Generation products, which are unlikely to have their nicotine content lowered. ‘Big Tobacco’ dominates the e-cigarette market, while the heat-not-burn category is led by Philip Morris International’s IQOS, which has already taken 12% of the Japanese market (and will be licensed to Altria in the U.S.), followed by BAT’s glo. The regulator’s attitude should help the approval of heat-not-burn in the U.S. and may even strengthen the case for favorable tax treatment compared to combustible cigarettes, as has been the case in other markets. This should ensure that the products have economics as good, or even better, than traditional cigarettes, once scale is reached.

Our view is that the world is a profoundly unpredictable place at present, and that this unpredictability is not reflected in a market where MSCI World Index is trading at close to 17 times the next 12 months’ earnings, which themselves include an assumption of double-digit earnings growth. As a result, we favor quality compounders, which can grow earnings steadily at high returns on operating capital. We put tobacco companies in that category, despite the regulatory noise, provided they are well placed in Next Generation products.

On the positive side, there was an explicit recognition in the FDA release that there are other less harmful means of delivering nicotine, a major endorsement of lower-risk Next Generation products, which are unlikely to have their nicotine content lowered. ‘Big Tobacco’ dominates the e-cigarette market, while the heat-not-burn category is led by Philip Morris International’s IQOS, which has already taken 12% of the Japanese market (and will be licensed to Altria in the U.S.), followed by BAT’s glo. The regulator’s attitude should help the approval of heat-not-burn in the U.S. and may even strengthen the case for favorable tax treatment compared to combustible cigarettes, as has been the case in other markets.

We favor quality compounders, which can grow earnings steadily at high returns on operating capital.”
IMPORTANT DISCLOSURES

The views and opinions are those of the author as of the date of publication and are subject to change at any time due to market or economic conditions and may not necessarily come to pass. Furthermore, the views will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date of publication. The views expressed do not reflect the opinions of all portfolio managers at Morgan Stanley Investment Management (MSIM) or the views of the firm as a whole, and may not be reflected in all the strategies and products that the Firm offers.

Forecasts and/or estimates provided herein are subject to change and may not actually come to pass. Information regarding expected market returns and market outlooks is based on the research, analysis and opinions of the authors. These conclusions are speculative in nature, may not come to pass and are not intended to predict the future performance of any specific Morgan Stanley Investment Management product.

Certain information herein is based on data obtained from third-party sources believed to be reliable. However, we have not verified this information, and we make no representations whatsoever as to its accuracy or completeness.

All information, which is not impartial, is provided for informational and educational purposes only and should not be deemed as a recommendation. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

RISK WARNINGS

There is no assurance that a portfolio will achieve its investment objective. Portfolios are subject to market risk, which is the possibility that the market value of securities owned by the portfolio will decline. Accordingly, you can lose money investing in this strategy. Please be aware that this strategy may be subject to certain additional risks. Changes in the worldwide economy, consumer spending, competition, demographics and consumer preferences, government regulation and economic conditions may adversely affect global franchise companies and may negatively impact the strategy to a greater extent than if the strategy’s assets were invested in a wider variety of companies. In general, equity securities values also fluctuate in response to activities specific to a company. Investments in foreign markets entail special risks such as currency, political, economic, and market risks. Stocks of small-capitization companies carry special risks, such as limited product lines, markets and financial resources, and greater market volatility than securities of larger, more established companies. The risks of investing in emerging market countries are greater than risks associated with investments in foreign developed markets. Non-diversified portfolios often invest in a more limited number of issuers. As such, changes in the financial condition or market value of a single issuer may cause greater volatility.

This communication is not a product of Morgan Stanley’s Research Department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

There is no guarantee that any investment strategy will work under all market conditions, and each investor should evaluate their ability to invest for the long-term, especially during periods of downturn in the market. Prior to investing, investors should carefully review the strategy’s/product’s relevant offering document. There are important differences in how the strategy is carried out in each of the investment vehicles.

U.S.

A separately managed account may not be suitable for all investors. Separate accounts managed according to the Strategy include a number of securities and will not necessarily track the performance of any index. Please consider the investment objectives, risks and fees of the Strategy carefully before investing. A minimum asset level is required. For important information about the investment manager, please refer to Form ADV Part 2.

Please consider the investment objectives, risks, charges and expenses of the funds carefully before investing. The prospectuses contain this and other information about the funds. To obtain a prospectus please download one at morganstanley.com/im or call 1-800-548-7786. Please read the prospectus carefully before investing.

Morgan Stanley Distribution, Inc. serves as the distributor for Morgan Stanley Funds.

NOT FDIC INSURED | OFFER NOT BANK GUARANTEED | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A BANK DEPOSIT

All information contained herein is proprietary and is protected under copyright law.

Morgan Stanley Investment Management is the asset management division of Morgan Stanley.